Scientists May Need to Rethink How Genomics Impacts Risk for OCD
Results of Mount Sinai-led study highlights the contribution of rare differences in an individual’s DNA sequences to disease risk
Both rare and commonly observed differences in the DNA letters strung along a person’s chromosomes can explain about a third of the risk for being diagnosed with obsessive-compulsive disorder (OCD), according to a new study led by scientists at the Icahn School of Medicine at Mount Sinai.
The researchers analyzed the genomic data of more than 2,000 Swedish-born individuals diagnosed with OCD. Their results, published in the American Journal of Psychiatry, may alter not only how scientists view the role that genomics plays in OCD but also how new treatments might be developed.
The study was led by scientists in the laboratory of Dorothy Grice, MD, Professor of Psychiatry at Icahn Mount Sinai.
Affecting about two percent of Americans, OCD describes a set of potentially life-long and debilitating symptoms, most notably intense and distressing recurring thoughts and actions. Although scientists have yet to find the exact causes of OCD, several studies indicate that multiple genomic and environmental factors may play a role in the disease. For instance, it has been estimated that anywhere between 25 to 50 percent of the risk for OCD behaviors may be attributable to genomic differences between individuals in a population.
Led by Behrang Mahjani, PhD, a researcher in Dr. Grice’s lab, the researchers compared the single nucleotide polymorphisms (SNPs)—the minor DNA spelling differences normally found in a person’s chromosomes—of 2,090 Swedish-born OCD patients with that of 4,567 controls, making it the largest study of its kind to date. Initial results supported previous studies. About 29 percent of the risk for OCD was attributed to differences in SNPs between patients and control subjects and about 90 percent of these differences are commonly observed throughout the general population. However, the researchers also found that about 10 percent of the risk could be linked to rare genomic differences, which were not seen in previous studies. Further analysis showed that the OCD-related SNPs were distributed across patients’ chromosomes, suggesting that multiple genomic differences combine to influence risk. Overall the results support the idea that OCD risk may, in part, be driven by randomly occurring changes to the entire genome rather than a few naturally selected “hot spots.” The researchers concluded that this new view of OCD highlights the important role of rare genomic differences in the risk of OCD, and may alter how scientists study the disorder to develop new treatments for patients.
Who: Behrang Mahjani, PhD, instructor, Department of Psychiatry at Icahn Mount Sinai; Dorothy Grice, MD, Professor of Psychiatry at Icahn Mount Sinai.
This study was supported by the National Institutes of Health (MH124679, MH057881, MH110427, MH120170, MH119084, and MH109528); the Friedman Brain Institute; the Beatrice and Samuel A. Seaver Foundation; the Mindworks Charitable Lead Trust; the Stanley Center for Psychiatric Research; the Swedish Research Council (2015-02271, 2018-02487, 538-2013-8864); the Center for Innovative Medicine (Sweden); the Klarman Family Foundation, the Brain and Behavior Research Foundation; and the Lundbeck Foundation (R276-2018-4581).
Article
Behrang, M., Klei, L., Mattheison, M. et al., The genetic architecture of obsessive-compulsive disorder: alleles across the frequency spectrum contribute liability to OCD. American Journal of Psychiatry, November 18, 2021, DOI:10.1176/appi.ajp.2021.21010101.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. The Health System includes approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses across seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, a school of nursing, and schools of medicine and graduate school of biomedical sciences.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York and recognized as one of the world’s top Smart Hospital by Newsweek. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools for National Institutes of Health (NIH) funding and No. 1 among freestanding medical schools, reflecting the strength of its scientific enterprise and leadership in biomedical research.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.